Premium
The CD 9 + CD 11b − HLA ‐ DR − immunophenotype can be used to diagnose acute promyelocytic leukemia
Author(s) -
Ren Fanggang,
Zhang Na,
Xu Zhifang,
Xu Jing,
Zhang Yaofang,
Chen Xiuhua,
Tan Yanhong,
Chang Jianmei,
Wang Hongwei
Publication year - 2019
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12929
Subject(s) - acute promyelocytic leukemia , immunophenotyping , antibody , myeloid leukemia , immunology , antigen , cd117 , medicine , myeloid , microbiology and biotechnology , cd34 , chemistry , biology , biochemistry , stem cell , retinoic acid , genetics , gene
Objective To investigate the immunophenotypic characteristics of acute promyelocytic leukemia ( APL ) and explore the sensitivity and specificity of various antibody combinations for the timely and accurate diagnosis APL . Methods A retrospective analysis was performed using morphological, immunological, genetic, and molecular biological data from 92 patients diagnosed with APL and 190 controls diagnosed with non‐ APL acute myeloid leukemia. Results For APL diagnosis, the CD 9/ CD 11b/human leukocyte antigen ( HLA )‐ DR antibody combination had 85% sensitivity and 95% specificity, AUC = 0.85. However, the sensitivity and specificity were 39% and 92%, AUC = 0.65, respectively, for the HLA ‐ DR / CD 34/ CD 117 combination, and 80% and 80%, AUC = 0.80, respectively for the CD 11b/ HLA ‐ DR combination. Significant differences were observed between the different antibody combinations. Conclusions The CD 9/ CD 11b/ HLA ‐ DR antibody combination displays high sensitivity and specificity and can be used to diagnose APL .